Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE

por Crauwels, HM, van Schaick, E, van Heeswijk, RPG, Vanveggel, S, Boven, K, Vis, P
Publicado 2010

Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics

por Admiraal, M. M., Velseboer, D. C., Tjabbes, H., Vis, P., Peeters-Scholte, C., Horn, J.
Publicado 2023

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

por Sekar, V, De La Rosa, G, Van de Casteele, T, Spinosa-Guzman, S, Vis, P, Hoetelmans, RMW
Publicado 2010

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to <12 Years

por Brochot, A, Kakuda, TN, Van De Casteele, T, Opsomer, M, Tomaka, FL, Vermeulen, A, Vis, P
Publicado 2015

The pathophysiological basis of pharmacological interventions in CAVD

por Riem Vis, P. W., van Rijswijk, J-W., Chamuleau, S. A. J., Vink, A., van Herwerden, L. A., Kluin, J.
Publicado 2011